139 related articles for article (PubMed ID: 34952136)
1. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
Wang Y; Sparidans RW; Wang J; Li W; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2022 Jan; 170():197-207. PubMed ID: 34952136
[TBL] [Abstract][Full Text] [Related]
2. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation.
Wang Y; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Br J Pharmacol; 2020 Jul; 177(13):3060-3074. PubMed ID: 32087611
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
[TBL] [Abstract][Full Text] [Related]
4. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib.
Li W; Tibben M; Wang Y; Lebre MC; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2020 Mar; 146(6):1631-1642. PubMed ID: 31304590
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
7. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract][Full Text] [Related]
9. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
F Martins ML; Loos NHC; Mucuk S; de Jong D; Lebre MC; Rosing H; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2021 Dec; 18(12):4371-4384. PubMed ID: 34730366
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
Wang Y; Sparidans RW; Potters S; Şentürk R; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832869
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 restricts brain accumulation of the novel RORγ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability.
Li W; Lehutová D; Sparidans RW; Heydari P; Wang J; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2022 Aug; 177():135-146. PubMed ID: 35772614
[TBL] [Abstract][Full Text] [Related]
12. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation.
Hendrikx JJ; Lagas JS; Wagenaar E; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Br J Cancer; 2014 May; 110(11):2669-76. PubMed ID: 24781280
[TBL] [Abstract][Full Text] [Related]
13. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure.
Wang J; Susam MM; Gan C; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145346
[TBL] [Abstract][Full Text] [Related]
14. ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability.
Li W; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834176
[TBL] [Abstract][Full Text] [Related]
15. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
16. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Mol Pharm; 2012 Nov; 9(11):3236-45. PubMed ID: 23020847
[TBL] [Abstract][Full Text] [Related]
17. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
[TBL] [Abstract][Full Text] [Related]
18. ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib.
Li W; Sparidans RW; Martins MLF; El-Lari M; Lebre MC; van Tellingen O; Beijnen JH; Schinkel AH
Mol Cancer Ther; 2021 Jun; 20(6):1173-1182. PubMed ID: 33785654
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
